Lafora's disease gene

Details Lafora's disease gene Lafora's disease gene

2011-01-18

2011-01-18

Goldberg, Jeanine A (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S091200, C536S023100, C536S024300

Reexamination Certificate

active

07871768

ABSTRACT:
A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described.

REFERENCES:
patent: 6825328 (2004-11-01), Scherer et al.
patent: 7550571 (2009-06-01), Delgado-Escueta et al.
patent: 2003/0092019 (2003-05-01), Meyer et al.
patent: 2004/0241740 (2004-12-01), Scherer et al.
patent: 2010/0009346 (2010-01-01), Scherer et al.
patent: 0705842 (1996-04-01), None
patent: WO 00/05405 (2000-02-01), None
patent: WO 00/05405 (2000-02-01), None
patent: WO2004038003 (2004-05-01), None
patent: WO 2005/012526 (2005-02-01), None
Ianzano et al. Human Mutation Database in Brief #847, 2008.
http://projects.tcag.ca/Iafora, Aug. 22, 2008.
Lohi et al. (Neurology, vol. 68, pp. 996-1001, 2007).
Chan et al. (J. Med. Genet. vol. 40, pp. 671-675, 2003).
Chan et al. (Nature Genetics, vol. 35, No. 2, pp. 125-127, Sep. 2003).
Singh et al. (J. Med Genetics, vol. 43, e48, 2006).
Lucentini (The Scientist; 2004, vol. 24, p. 20).
Hirschhorn et al. (Genetics in Medicine. vol. 4, No. 2, pp. 45-61, Mar. 2002).
Ioannidis (Nature Genetics, vol. 29, pp. 306-309, Nov. 2001).
Chan et al. (Nature Genetics, vol. 35, No. 2, pp. 125-127, Oct. 2003).
Denu, J., et al., “Form and Function in Protein Dephosphorylation,”Cell, vol. 87, pp. 361-364, Nov. 1, 1996.
Roes, et al., “Mouse Anti-Mouse IgD Monoclonal Antibodies Generated in IgD-Deficient Mice,” Journal of Immunological Methods, pp. 231-237, 1995.
GenBank, Accession AJ130763, GI 3980308, Dec. 16, 1998.
deJong, P.J. “Preparation of PAC Libraries, Final Technical Report,” Report No. DE-FG02-94ER61883—1, 7 pages plus cover sheet (Dec. 1997).
U.S. Office Action dated May 2, 2007 for U.S. Appl. No. 10/886,033.
U,S. Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/886,033.
U.S. Office Action dated May 23, 2008 for U.S. Appl. No. 10/886,033.
U.S. Office Action dated Nov. 28, 2008 for U.S. Appl. No. 10/886,033.
U.S. Office Action dated Dec. 24, 2002 for U.S. Appl. No. 09/744,072.
U.S. Office Action dated Oct. 22, 2003 for U.S. Appl. No. 09/744,072.
U.S. Office Action dated Mar. 18, 2010 for U.S. Appl. No. 11/979,262.
Canadian Office Action dated Apr. 22, 2010 for Canadian Application No. 2,338,250.
Wojcik, S.F., et al., “Cloning of Bovine Parathyroid Hormone-Related Protein (PTHrP) cDNA and Expression of PTHrP mRNA in the Bovine Mammary Gland,”J. Mol. Endocrinol., 20:271-280 (1998).
Serratosa, J.M., et al., “A Novel Protein Tyrosine Phosphatase Gene is Mutated in Progressive Myoclonus Epilepsy of the Lafora Type (EPM2),”Human Molecular Genetics8(2):345-352 (1999).
Sainz, J., et al., “Lafora Progressive Myoclonus Epilepsy: Narrowing the Chromosome 6q24 Locus by Recombinations and Homozygosities,”Am. J. Hum. Genet., 61:1205-1209 (1997).
Lehesjoki, Anna-Elina, “Molecular Background of Progressive Myoclonus Epilepsy,”The EMBO Journal22(14):3473-3478 (2003).
Chan, E.M., et al., “Mutations in NHLRC1 Cause Progressive Myoclonus Epilepsy,”Nature Genetics35(2):125-127 (2003).
Minassian, B.A., et al., “Mutations in a Gene Encoding a Novel Protein Tyrosine Phosphatase Cause Progressive Myoclonus Epilepsy,”Nature Genetics20:171-174 (1998).
Chan, E.M., et al., “Genetic Mapping of a New Lafora Progressive Myoclonus Epilepsy Locus (EPM2B) on 6p22,”J. Med. Genet., 40:671-675 (2003).
Minassian, B.A., et al., “Progress Towards the Positional Cloning of a Gene for Lafora's Disease,”Neurology48:A428 (1997).
Database Sequence, Genbank Accession No. AK045746, 2006.
Database Sequence, Genbank Accession No. AL589723, 2007.
Database Sequence, Genbank Accession No. CAE62664, 2003.
Database Sequence, Genbank Accession No. AL023806, 2007.
Cavanagh, J.B., “Corpora-amylacea and the Family of Polyglucosan Diseases,”Brain Research Reviews29: 265-295 (1999).
Freemont, Paul S., “Ubiquitination: RING for Destruction?”Current Biology10: R84-R87 (2000).
Fridell, Robert A., et al., “Identification of a Novel Human Zinc Finger Protein that Specifically Interacts with the Activation Domain of Lentiviral Tat Proteins,”Virology209: 347-357 (1995).
Ganesh, Subramaniam, et al., “Targeted Disruption of theEpm2aGene Causes Formation of Lafora Inclusion Bodies, Neurodegeneration, Ataxia, Myoclonus Epilepsy and Impaired Behavioral Response in Mice,”Human Molecular Genetics11(11): 1251-1262 (2002).
Ganesh, Subramaniam, et al., “Alternative Splicing Modulates Subcellular Localization of Laforin,”Biochemical and Biophysical Research Communications291: 1134-1137 (2002).
Ganesh, Subramaniam, et al., “Laforin, Defective in the Progressive Myoclonus Epilepsy of Lafora Type, is a Dual-Specificity Phosphatase Associated with Polyribosomes,”Human Molecular Genetics9(15): 2251-2261 (2000).
Hatakeyama, Shigetsugu, and Nakayama , Kei-ichi I., “U-box Proteins as a New Family of Ubiquitin Ligases,”Biochemical and Biophysical Research Communications302: 635-645 (2003).
Ianzano, Leonarda, et al., “Identification of a Novel Protein Interacting with Laforin, theEPM2AProgressive Myoclonus Epilepsy Gene Product,”Genomics81: 579-587 (2003).
Jackson, Peter K., et al., “The Lore of the RINGs: Substrate Recognition and Catalysis by Ubiquitin Ligases,”Cell Biology10: 429-439 (2000).
Lalioti, Maria D., et al., “Dodecamer Repeat Expansion in Cystatin B Gene in Progressive Myoclonus Epilepsy,”Nature386: 847-851 (1997).
Licht, Barbara G., et al., “Clinical Presentations of Naturally Occurring Canine Seizures: Similarities to Human Seizures,”Epilepsy&Behavior3: 460-470 (2002).
Lossos, Alexander, M.D., et al., “Adult Polyglucosan Body Disease in Ashkenazi Jewish Patients Carrying the TYR329Ser Mutation in the Glycogen-Branching Enzyme Gene,”Annals of Neurology, 44(6): 867-872 (1998).
Minassian, B.A., M.D., et al. “Mutation Spectrum and Predicted Function of Laforin in Lafora's Progressive Myoclonus Epilepsy,”Neurology55: 341-346 (2000).
Minassian, Berge A., et al., “Laforin is a Cell Membrane and Endoplasmic Reticulum-Associated Protein Tyrosine Phosphatase,”Annals of Neurology49(2): 271-275 (2001).
Minassian, Berge A., M.D., et al., “Genetic Locus Heterogeneity in Lafora's Progressive Myoclonus Epilepsy,”Annals of Neurology5(2): 262-265 (1999).
Schoeman, Tanya, et al., “Polyglucosan Storage Disease in a Dog Resembling Lafora's Disease,”J. Vet. Intern. Med.16: 201-207 (2002).
Thon, Vicki J., et al., “Isolation of Human Glycogen Branching Enzyme cDNAs by Screening Complementation in Yeast,”The Journal of Biological Chemistry, 268(10): 7509-7513 (1993).
Weinhaeusel, Andreas, et al., “DNA Deamination Enables Direct PCR Amplification of the Cystatin B (CSTB) Gene-Associated Dodecamer Repeat Expansion in Myoclonus Epilepsy Type Unverricht-Lundborg,”Human Mutation22: 404-408 (2003).
Japanese Office Action dated May 26, 2010 for Japanese Patent Application No. 2006-522189.
Collins, F., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”,PNAS, vol. 99(26), pp. 16899-16903 (Oct. 2002).

Affiliated with

Also associated with

Rating

Lafora's disease gene does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lafora's disease gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lafora's disease gene will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2638601